Precipio (PRPO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
CEO welcomed shareholders, introduced directors, officers, and board observers, and called the meeting to order.
Chief Legal and People Officer was appointed to record minutes and explain Q&A procedures for shareholders.
Meeting agenda and proposals were outlined, with reference to the proxy statement and voting process.
Board and executive committee updates
Three current board members were nominated for re-election as Class II directors for three-year terms expiring in 2029.
Shareholder proposals
Two proposals were presented: election of directors and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Precipio
- Q1 revenue up 36% YoY; shipment delays, CMS cuts, and losses drive ongoing going concern risks.PRPO
Q1 202619 May 2026 - Annual meeting to elect directors, ratify auditor, and reinforce governance and compensation alignment.PRPO
Proxy filing29 Apr 2026 - Director elections and auditor ratification headline the June 2026 annual meeting agenda.PRPO
Proxy filing28 Apr 2026 - Positive cash flow and 30% revenue growth in 2025 set the stage for accelerated product expansion.PRPO
Q4 20252 Apr 2026 - Q2 2025 net sales up 27%, gross margin at 43%, with positive net income but ongoing risks.PRPO
Q2 202527 Jan 2026 - Q1 2025 revenue up 44% to $4.9M, gross margin 43%, net loss narrowed, but risks remain.PRPO
Q1 202527 Jan 2026 - Q3 2025 saw 30% revenue growth, positive EBITDA, 44% margin, but going concern risk persists.PRPO
Q3 202527 Jan 2026 - Net sales and pathology revenues rose, but losses and liquidity concerns remain.PRPO
Q3 202427 Jan 2026 - Q2 2024 revenue up 26% to $4.4M, losses narrowed, but going concern risks remain.PRPO
Q2 202427 Jan 2026